Agios Reports Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Agios Pharma (AGIO) Misses Q4 EPS by 8c
February 25, 2021 7:50 AM ESTAgios Pharma (NASDAQ: AGIO) reported Q4 EPS of ($1.41), $0.08 worse than the analyst estimate of ($1.33). Revenue for the quarter came in at $44 million versus the consensus estimate of $40.17 million.
For earnings history and earnings-related data on Agios Pharma (AGIO) click here.
... More